Evolution of postmenopausal hormone therapy between 2002 and 2009
- 1 June 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Menopause
- Vol. 19 (6), 610-615
- https://doi.org/10.1097/gme.0b013e31823a3e5d
Abstract
The results of the Women’s Health Initiative led to a sharp decline in postmenopausal hormone therapy use. Subsequently, treatment guidelines were revised to recommend hormone therapy at the lowest effective dose for the shortest possible duration. The objective of this analysis was to assess trends in nationwide hormone therapy prescription claims from 2002 to 2009. This study was a retrospective database analyses of pharmacy claims from MedImpact Healthcare Systems Inc. Data from women with claims for oral or transdermal hormone therapy were analyzed to assess trends in hormone therapy claims, including route of administration, dose, and physician specialty. By the end of 2002, the total number of hormone therapy claims dropped approximately 30% from 2002 second quarter claims. This trend continued during the next 7 years, and by 2009, hormone therapy claims were reduced by more than 70%. The proportion of low--dose oral claims rose fourfold, whereas the proportion of standard/high-dose claims decreased 30%. The proportion of claims for transdermal formulations more than doubled, and the proportion of claims for low-dose transdermal hormone therapy increased 10-fold. Although reductions in overall claims, routes of administration, and dose categories were similar between physician specialties, obstetrician/gynecologists prescribed transdermal hormone therapy nearly twice as often as all other types of providers. Since the publication of the Women’s Health Initiative results, there has been a sustained decrease in hormone therapy claims. The proportional use of low-dose oral and transdermal formulations has increased, but as of 2009, claims for these formulations accounted for approximately one in four total hormone therapy claims.Keywords
This publication has 23 references indexed in Scilit:
- Cessation of Hormone Replacement Therapy After Reports of Adverse Findings From Randomized Controlled Trials: Evidence From a British Birth CohortAmerican Journal of Public Health, 2006
- Health System Responses to the Women's Health Initiative Findings on Estrogen and Progestin: Organizational ResponseJNCI Monographs, 2005
- Guidelines for hormone treatment of women in the menopausal transition and beyond: Position Statement by the Executive Committee of the International Menopause SocietyMaturitas, 2005
- The Impact of the Women's Health Initiative on Hormone Replacement Therapy in a Medicaid ProgramJournal of Women's Health, 2004
- Vasomotor SymptomsObstetrics & Gynecology, 2004
- Changes in the Use of Postmenopausal Hormone Therapy after the Publication of Clinical Trial ResultsAnnals of Internal Medicine, 2004
- National Use of Postmenopausal Hormone TherapyPublished by American Medical Association (AMA) ,2004
- Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society: RetractedMenopause, 2004
- Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapyObstetrics & Gynecology, 2003
- Use of Hormone Replacement Therapy by Postmenopausal Women in the United StatesAnnals of Internal Medicine, 1999